Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 30, 2025

Stock market today: Dow, S&P 500, Nasdaq waver as Fed minutes show division over December rate cut

View original at finance.yahoo.com
Stock market today: Dow, S&P 500, Nasdaq waver as Fed minutes show division over December rate cut US stocks wavered after the opening bell on Tuesday, as Wall Street looked to regroup after a tech-led slide to begin the final stretch of 2025…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • If federal budgetary actions push the market downward, Molina's shares could drop below $100, which he labeled a generational buy.

    80% confidence
  • Molina Healthcare has the best loss ratio, best expense ratio, best win rate, and most conservative accounting among insurers.

    80% confidence
  • Globally, supply on metals from lithium to cobalt has been heavily constrained by a mixture of government policy and natural resource decline, and mining companies have faced a mix of pressures including ESG policies, long permitting timelines, and self-imposed capital efficiency requirements following the commodity price bust in the 2010s.

    80% confidence
  • Metals and mining sector tailwinds should continue in early 2026, and the sector should outperform again as a result.

    80% confidence
  • We're in a metals war

    80% confidence
  • Molina Healthcare has a clearer path to significant double-digit long-term growth than Apple.

    80% confidence
  • Michael Burry stated he would acquire Molina Healthcare if he had the funds.

    80% confidence
  • Tesla estimated Q4 deliveries at a 15% drop compared to the same period last year.

    80% confidence
  • Most participants judged that further downward adjustments to the target range for the federal funds rate would likely be appropriate if inflation declined over time as expected.

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com